Akoya Biosciences, Inc. (AKYA)
Automate Your Wheel Strategy on AKYA
With Tiblio's Option Bot, you can configure your own wheel strategy including AKYA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AKYA
- Rev/Share 1.61
- Book/Share -0.1186
- PB -10.7105
- Debt/Equity -14.2168
- CurrentRatio 0.6126
- ROIC -0.4579
- MktCap 63341758.0
- FreeCF/Share -0.6512
- PFCF -1.9584
- PE -1.327
- Debt/Assets 0.7432
- DivYield 0
- ROE -5.0583
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal
Published: May 23, 2025 by: PRNewsWire
Sentiment: Neutral
RINCON, Puerto Rico , May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ: AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya.
Read More
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Biosciences, Inc. (NasdaqGS: AKYA) to Quanterix Corporation (NasdaqGM: QTRX). Under the terms of the proposed transaction, shareholders of Akoya will receive 0.318 shares of Quanterix for each share of Akoya that they own. KSF is seeking to determine whether this consideration and the process that led to.
Read More
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences
Published: February 18, 2025 by: Business Wire
Sentiment: Neutral
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of 5.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today highlighted its opposition to the Company's proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA). Kent Lake has also issued an open letter to all Quanterix shareholders outlining how the Merger significantly undervalues the Company and its intention to take all necessary step.
Read More
About Akoya Biosciences, Inc. (AKYA)
- IPO Date 2021-04-16
- Website https://www.akoyabio.com
- Industry Medical - Instruments & Supplies
- CEO Mr. Brian McKelligon
- Employees 205